Saros Therapeutics is working to enhance patients' response to immunotherapy by harnessing the STING pathway with a strategy to overcome the limitations of prior STING agonists. In combination with existing immunotherapies, this approach has the potential to enable a safe and more effective immune response against the tumor than with immunotherapy alone.